Treatment of patients who have fibrodysplasia ossificans progressiva with isotretinoin

Clinical Orthopaedics and Related Research

Volumn 346, Issue , 1998, Pages 121-129

  Zasloff, Michael A ^a,b   Rocke, David M ^c   Crofford, Leslie J ^a   Hahn, Gregory V ^b   Kaplan, Frederick S ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA AT DAVIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETIDRONIC ACID; ISOTRETINOIN;

ADOLESCENT; ADULT; BONE SCINTISCANNING; CARTILAGE; CHEILITIS; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRY SKIN; FEMALE; HUMAN; INCIDENCE; MALE; MESENCHYME CELL; ORAL DRUG ADMINISTRATION; OSSIFICATION; OSSIFYING MYOSITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEADY STATE; TISSUE INDUCTION;

EID: 0031963441     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-199801000-00018     Document Type: Conference Paper

References (49)

1. Anderson PK, Ornulf B, Gill RD, Keiding N: Statistical Models Based on Counting Processes. New York, Springer-Verlag, 1993.
2. Ayers DC, Pellegrini Jr VD, Evarts CM: Prevention of heterotopic ossification in high-risk patients by radiation therapy. Clin Orthop 263:87-93, 1991.
3. Bailar III JC, Louis TA, Lavori PW, Polansky M: Statistics in practice: Studies without internal controls. N Engl J Med 311:156-162, 1984.
4. Beighton P: Fibrodysplasia Ossificans Progressiva. In: McKusick VA (ed). McKusick's Heritable Disorders of Connective Tissue. Ed 5 St Louis, C V Mosby 501-518, 1993.
5. Carey BM, Parkin GJS, Cunliffe WJ, Pritlove J: Skeletal toxicity with isotretinoin therapy: A clinicoradiological evaluation. Br J Dermatol 119:609-614, 1988.
6. Castleberry RP, Emanuel PD, Zuckerman KS, et al: A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 331:1680-1684, 1994.
7. Cohen RB, Hahn GV, Tabas JA, et al: The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surgery 75A:215-219, 1993.
8. Connor JM: Fibrodysplasia ossificans progressiva - lessons from rare maladies (editorial). N Engl J Med 335:591-593, 1996.
9. Connor JM, Evans D: Fibrodysplasia ossificans progressiva. The clinical features and natural history in 34 patients. J Bone Joint Surgery 64B:76-83, 1982.
10. Connor JM, Skirton H, Lunt PW: A three generation family with fibrodysplasia ossificans progressiva. J Med Genet 30:687-689, 1993.
11. Cox DR, Oakes D: Analysis of Survival Data. London, Chapman & Hall Inc 1984.
12. ∧ JC: Failure of surgery and isotretinoin to relieve jaw immobilization of fibrodysplasia ossificans progressiva. J Oral Maxillofac Surg 48:204-208, 1990.
13. DeSimone DP, Reddi AH: Influence of vitamin A on matrix-induced endochondral bone formation. Calcif Tissue Int 35:732-739, 1983.
14. DiGiovanna JJ, Holfgott RK, Gerber LH, Peck GL: Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. N Engl J Med 315:1177-1182, 1986.
15. DiGiovanna JJ, Peck GL: Oral synthetic retinoid treatment in children. Pediatr Dermatol 1:77-88, 1983.
16. Ellis CN, Madison KC, Pennes DR, Martel W, Voorhees JJ: Isotretinoin therapy is associated with early skeletal radiographic changes. J Am Acad Dermatol 10:1024-1029, 1984.
17. Ellis CN, Pennes DR, Hermann RC, et al: Long-term radiographic follow-up after isotretinoin therapy. J Am Acad Dermatol 18:1252-1256, 1988.
18. Fanjul A, Dawson MI, Hobbs PD, et al: A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372:107-111, 1994.
19. Fleming TR, Harrington DP: Counting Processes and Survival Analysis. New York, John Wiley Inc, 1991.
20. Glozak MA, Rogers MB: Specific induction of apoptosis in P19 embryonal carcinoma cells by retinoic acid and BMP 2 or BMP 4. Developmental Biol 179:458-470, 1996.
21. Hellman S, Hellman DS: Of mice but not men: Problems of the randomized clinical trial. N Engl J Med 324:1585-1589, 1991.
22. Jones H, Blanc D, Cunliffe WJ: 13-cis-retinoic acid and acne. Lancet 2:1048-1049, 1980.
23. Inoue K, Imai S, Iwasaki A, Egawa M, Hukuda S: Etretinate-induced heterotopic bone formation about the hip. Clin Orthop 308:139-145, 1994.
24. Kaplan FS, McCluskey W, Hahn GV, et al: Genetic transmission of fibrodysplasia ossificans progressiva: Report of a family. J Bone Joint Surg 75A:1214-1220, 1993.
25. Kaplan FS, Tabas JA, Gannon FH, et al: The histopathology of fibrodysplasia ossificans progressiva: An endochondral process. J Bone Joint Surg 75A:220-229, 1993.
26. Kaplan FS, Tabas JA, Zasloff MA: Fibrodysplasia ossificans progressiva: A clue from the fly. Calcif Tissue Int 47:117-125, 1990.
27. Kochnar DM: Limb development in mouse embryos. Analysis of teratogenic effects of retinoic acid. Teratology 7:289-298, 1973.
28. Lippman SM, Batsakis JG, Toth BB, et al: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20, 1993.
29. Lotan R, Xu X-C, Lippman SM, Ro Jy, et al: Suppression of retinoic acid receptor-β in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 332:1405-1410, 1995.
30. Mitchell AA, Van Bennekom CM, Louik C: A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 333:101-106, 1995.
31. Peck GL, Olsen TG, Yoder FW, et al: Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 300:329-333, 1979.
32. Pennypacker JP, Lewis CA, Hassel JR: Altered proteoglycan metabolism in mouse limb mesenchymal cell cultures treated with vitamin A. Arch Biochem Biophys 186:351-358, 1978.
33. Phillips TJ, Dover JS: Recent advances in dermatology. N Engl J Med 326:167-178, 1992.
34. Pittsley RA, Yoder FW: Retinoid hyperostosis: Skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. N Engl J Med 308:1012-1014, 1983.
35. Roberts DJ, Tabin C: The genetics of human limb development. Am J Hum Genet 55:1-6, 1994.
36. Rocke DM, Zasloff M, Peeper J, Cohen RB, Kaplan FS: Age and joint specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin Orthop 301:243-248, 1994.
37. Rogers JG, Geho WB: Fibrodysplasia ossificans progressiva. A survey of 42 cases. J Bone Joint Surg 61A:909-914, 1979.
38. Rogers MB, Rosen V, Wozney JM, Gudas LJ: Bone morphogenetic proteins-2 and -4 are involved in the retinoic acid-induced differentiation of embryonal carcinoma cells. Mol Biol Cell 3:189-196, 1992.
39. Rothman KJ, Moore LL, Singer MR, et al: Teratogenicity of high vitamin A intake. N Engl J Med 333:1369-1373, 1995.
40. Roush W: Protein builds second skeleton. Science 273:1170, 1996.
41. Schroeder HW, Zasloff M: The hand and foot malformations in fibrodysplasia ossificans progressiva. J Hopkins Med J 147:73-78, 1980.
42. Shafritz AB, Shore EM, Gannon FH, et al: Over-expression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 335:555-561, 1996.
43. Shah PB, Zasloff MA, Drummond D, Kaplan FS: Spinal deformity in patients who have fibrodysplasia ossificans progressiva. J Bone Joint Surgery 76A:1442-1450, 1994.
44. Strauss JS, Rapini RP, Shalita AR, et al: Isotretinoin therapy for acne: Results of a multicenter dose-response study. J Am Acad Dermatol 10:490-496, 1984.
45. Tabin CJ: Retinoids, homeoboxes, and growth factors: toward molecular models for limb development. Cell 66:199-217, 1991.
46. Therneau T: A package for survival analysis in technical report No. 53. Section of biostatistics, The Mayo Clinic Rochester, NY.
47. Turnbull BW: Nonparametric estimation of survivorship function with double censored data. J Am Statistical Assoc 69:169-173, 1974.
48. Warrell Jr RP, de Thtx H, Wang Z-Y, Degos L: Acute promyelocytic leukemia. N Engl J Med 329:177-189, 1993.
49. Zhou H, Hammonds Jr RG, Findlay DM, et al: Retinoic acid modulation of mRNA levels in malignant, nontransformed and immortalized osteoblasts. J Bone Miner Res 6:767-777, 1991.